Skip to content
Skip to search
Skip to footer
- Odyssey- A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy- Mavacamten in non-obstructive HCM. Richard Bach, MD. Bristol-Myers Squibb.
IN FOLLOW-UP
view on clinicaltrials.gov
- Sonata-HCM- A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in symptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy. Richard Bach, MD. Lexicon Pharmaceuticals.
CURRENTLY ENROLLING
view on clinicaltrials.gov
- MAVA-LTE- A Long-Term Safety Extension Study of Mavacamten (MYK-461) inAdults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials. Richard Bach, MD. MyoKardia.
IN FOLLOW-UP
view on clinicaltrials.gov
- DISCOVER HCM- Observational Study Protocol CV027-012 Deliver insights in hypertrophic cardiomyopathy and observational outcomes in real world. Richard Bach, MD. Bristol-Myers Squibb.
IN FOLLOW-UP
view on clinicaltrials.gov
- Fortitude-HCM: A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy. Sharon Cresci, MD.
Pending Enrollment August 2025
view on clinicaltrials.gov